Sales@Broadpharm.com
858-677-6760
Login
Cart
Home
Products
Categories
Applications
PEG Linkers
Click Chemistry Reagents
ADC Linkers
Antibody Drug Conjugates (ADC), Oncology API
Thiol Reactive Linkers
Amine Reactive Linkers
Target-Specific Linkers
Polymer PEG, Copolymer
Lipids In Drug Delivery
Nucleoside, Nucleotide, Phosphoramidite
Amino Acid, Peptide
PROTAC
Fluorescent Dye
Biotinylation reagents
Bioconjugation Kits
NEW
PEG Linkers
Acrylate PEG
BCN-PEG
Boc-PEG
Diketone Linkers
Fluorescent reagent
Iodo PEG
Non-PEG linker
PEG Hydrazide
PEG Silane
Poly PEG
TCO-PEG
Alkyne PEG
Benzyl-PEG
Branched PEG
Disulfide Linkers
Fluorine PEG
Lipid PEG
NOTA reagent
PEG NHS ester
PEG Sulfonic acid
Propargyl PEG
Tetrazine-PEG
Amino PEG
Biotin PEG
Bromo PEG
DNP-PEG
Fmoc PEG
m-PEG
PEG Acid
PEG PFP ester
PEG Tosylate
PROTAC Linker
Thiol PEG
Aminooxy PEG
Bis-PEG-acid
Chloro PEG
DOTA reagent
Hybrid Linkers
Maleimide Linkers
PEG Aldehyde
PEG Phosphonate
PEG-X-PEG
SPDP PEG
APN PEG
Bis-PEG-NHS
DBCO PEG
Enzymatically Cleavable Linkers
Hydroxy PEG
MeNH-PEG
PEG Azide
PEG PNP carbonate
Photocleavable Linkers
Sugar PEG
PEGylation of Protein, Peptide & Oligo
Antibody Drug Conjugates
Drug Delivery, Surface Modification
PROTAC
Proteomics
Amine Reactive
Bis-PEG-acid
Bis-PEG-acid
Bis-PEG-NHS
Bis-PEG-NHS
Boc-PEG
Fmoc PEG
PEG Acid
PEG Acid
PEG Aldehyde
PEG Aldehyde
PEG NHS ester
PEG NHS ester
PEG PFP ester
PEG PFP ester
PEG Phosphonate
PEG Silane
PEG Tosylate
PEG Tosylate
Poly PEG
Carbonyl Reactive
Aminooxy PEG
Carboxyl and Active ester Reactive
Amino PEG
Click Chemistry Reactive
Alkyne PEG
BCN-PEG
DBCO PEG
PEG Azide
TCO-PEG
Tetrazine-PEG
Lipid Molecules
Branched Lipid
Cationic Lipid
Cholesterol
Helper Lipid
Ionizable Lipid
PEG Lipid
Phospholipid
Multi-arm PEG
Branched PEG
Thiol Reactive
Bromo PEG
Bromo PEG
Maleimide Linkers
Maleimide Linkers
Services
Order
Support
Custom Service
Protocols
QA/QC
Magic Link Guide
Works Cited
About
Company Info
News
Blog
Customer Feedback
Careers
Contact
United States
Distributors
Login
Cart
Camrelizumab Biosimilar, PD-1 Monoclonal Antibody
Home
/
Products
/
Antibody Drug Conjugates (ADC), Oncology API
/
Antibody
/
Camrelizumab Biosimilar, PD-1 Monoclonal Antibody
Camrelizumab Biosimilar, PD-1 Monoclonal Antibody
Catalog #: bp-50537
Catalog #
Unit
Price
Qty
BP-50537
1 mg
$200.00
BP-50537
5 mg
$700.00
Usually ships within 24 hours.
Would you like to inquire about custom quantity?
Inquire
Overview
Camrelizumab Biosimilar uses the same protein sequences as the therapeutic antibody camrelizumab. Camrelizumab is an IgG4κ humanized monoclonal antibody being investigated for hepatocellular carcinoma. It targets programmed cell death protein 1 (PD-1), a protein on the surface of cells, also known as CD279 (cluster of differentiation 279). Camrelizumab is being evaluated in the Phase 2/3 (NCT02989922) of patients with advanced hepatocellular carcinoma (HCC) in second-line after failure or intolerance to prior systemic treatment. The study has 2 arms in which patients will be intravenous administered 3 mg/kg SHR-1210 on day 1 every 2 weeks or every 3 weeks. The primary outcome measures are the overall response rate (ORR) and overall survival (OS) rates at 6 months with duration of response and OS at 2 years as secondary endpoints. The estimated enrollment is 220 patients, and the estimated primary completion date is December 2018. A randomized, open-label Phase 3 study (NCT03099382) is evaluating the efficacy of camrelizumab treatment compared to standard-of-care treatment (docetaxel or irinotecan) in patients with esophageal carcinoma. Patients are randomly assigned to receive either SHR-1210 (200 mg every 2 weeks) or the standard of care (docetaxel 75 mg/m2 on day 1 every 3 weeks or irinotecan 180 mg/m2 on day 1 every 2 weeks). This Phase 3 study has an estimated enrollment of 438 and an estimated primary completion date of June 2018.
Product Details
Species Reactivity
Human
Source
The camrelizumab biosimilar CHO stable cell line.
Host/Isotype
Human IgG4-k kappa
Class
Monoclonal
Type
Antibody
Immunogen
The human programmed cell death protein 1 (PD-1), antagonizing its interaction with its known ligands PD-L1 and PD-L2
Clone
Camrelizumab Biosimilar
Conjugate
Unconjugated
Purity
>95%
Molecular Weight
143.69 kDa
Protein Concentration
1 mg/ml
Formulation
Liquid
Storage Condition
4°C for short time, -20°C or -80°C for long time.
Storage Buffer
0.2 uM filtered PBS solution, pH 6.0
Images
Datasheets and Documents
Datasheet BP-50537.pdf
Other Related Products
Trastuzumab (Anti-HER2)
Gemtuzumab (Anti-Siglec-3 / CD33)
Disitamab (Anti-ERBB2 / HER2 / CD340)
Belantamab (Anti-TNFRSF17 / BCMA / CD269)